PellePharm to Present at Cantor Fitzgerald Global Healthcare Conference
SAN FRANCISCO--(BUSINESS WIRE)--Sep 25, 2018--PellePharm, a late clinical-stage biopharmaceutical company committed to targeting rare dermatologic conditions at their source, today announced that Sanuj K. Ravindran, M.D., chief executive officer and president, will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, at 4:35 p.m. ET in New York.
A live webcast of the presentation can be accessed on the company’s website at www.pellepharm.com. A replay of the webcast will be archived on the PellePharm website for at least two weeks following the presentation.
About PellePharm Founded by world leaders in hedgehog pathway signaling, PellePharm is a biotechnology company committed to targeting rare, genetic dermatological diseases, including Gorlin Syndrome and High-Frequency Basal Cell Carcinomas (BCCs), at their source. PellePharm’s mission is to improve the quality of life for those suffering from Gorlin Syndrome and High-Frequency BCCs by providing an easy-to-use topical solution that eliminates the need for regular, painful surgeries. Topical patidegib is a first-in-class topical gel formulation of a proprietary hedgehog inhibitor.
View source version on businesswire.com:https://www.businesswire.com/news/home/20180925005190/en/
CONTACT: W2O pure
Lauren Barbiero, 646-564-2156
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL
Copyright Business Wire 2018.
PUB: 09/25/2018 07:00 AM/DISC: 09/25/2018 07:01 AM